This ad hoc analysis reported up to 7 years of integrated efficacy and safety follow-up from MAGNOLIA, an open-label, single-arm, multicenter phase 2 study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL), and its long-term extension (LTE1).
MAGNOLIA was an open-label, single-arm, multicenter phase 2 study of zanubrutinib in patients with R/R MZL. Patients enrolling in LTE1 continued zanubrutinib at the same dose received in MAGNOLIA. This ad hoc analysis integrated efficacy and safety data across both studies. Safety was assessed every 3 months, while efficacy was evaluated every 6 months with regular restaging scans at the investigators’ discretion. All disease progression events were independently confirmed. Efficacy endpoints included investigator-assessed overall response rate (ORR), complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS); safety was also assessed.
Of 68 patients enrolled in MAGNOLIA, 66 were evaluable for efficacy. Thirty-six patients (52.9%) rolled over to LTE1, of whom 32 (47.1%) continued treatment with zanubrutinib and 4 (5.9%) were in survival follow-up. As of April 1, 2026, median study follow-up was 35.3 months (range, 1.6-84.3), with the longest individual follow-up reaching 7 years. Median treatment exposure across MAGNOLIA and LTE1 was 27.8 months (range, 0.9-82.0); 36 patients (52.9%) were treated for more than 2 years and 24 (35.3%) for more than 4 years.
The investigator-assessed ORR was 77.3% (95% CI, 65.3-86.7). With approximately 4 years of extended follow-up, the CR rate increased to 37.9% (95% CI, 26.2-50.7) from 28.8% at study closure of MAGNOLIA, with five patients previously assessed as partial response and one as stable disease converting to CR since the study closure of MAGNOLIA. Median time to response was 2.99 months.
Median DOR was 38.8 months (95% CI, 22.1-not estimable); DOR rates were 58.4% (95% CI, 43.5-70.6) at 36 months and 47.5% (95% CI, 33.0-60.6) at 60 months. Median PFS was 34.3 months (95% CI, 16.5-49.6); PFS rates were 48.1% (95% CI, 35.4-59.8) at 36 months, 37.8% (95% CI, 25.8-49.7) at 60 months, and 36.1% (95% CI, 24.3-48.0) at 72 months. Median OS was not reached; OS rates were 74.4% (95% CI, 60.8-83.9) at 60 months and 72.0% (95% CI, 58.0-82.1) at 72 months.
Serious treatment-emergent adverse events (TEAEs) occurred in 52.9% (n=36) of patients, grade ≥3 TEAEs in 60.3% (n=41), TEAEs leading to treatment discontinuation in 8.8% (n=6), and fatal TEAEs in 8.8%, of which 2.9% were due to COVID-19 pneumonia.